Warning: The NCBI web site requires JavaScript to function. more...
The future of cytotoxic therapy: selective cytotoxicity based on biology is the key.
de Bono JS, Tolcher AW, Rowinsky EK.
Breast Cancer Res. 2003;5(3):154-9. Epub 2003 Mar 27. Review.
Related citations
The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P.
Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S45-56. Epub 2003 Jun 18. Review.
Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
Rowinsky EK.
J Clin Oncol. 2003 May 15;21(10 Suppl):175s-186s. Review.
Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.
Adv Exp Med Biol. 2007;608:1-22. Review.
[Development of antituberculous drugs: current status and future prospects].
Tomioka H, Namba K.
Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.
New therapeutic strategies for soft tissue sarcomas.
von Mehren M.
Curr Treat Options Oncol. 2003 Dec;4(6):441-51. Review.
Novel anticancer agents in clinical development.
Adjei AA, Rowinsky EK.
Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S5-15. Review.
Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignancies.
Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4220s-4226s.
Optimal duration of chemotherapy in advanced non-small cell lung cancer.
Lustberg MB, Edelman MJ.
Curr Treat Options Oncol. 2007 Feb;8(1):38-46. Review.
[Future directions of anticancer drug development in Japan].
Akaza H, Kawai K, Tsuruo T, Tsukagoshi S, Aiba K, Shimada Y, Kakeji Y, Ishikawa H, Ikeda T, Nakamura S, Tamura T, Yamamoto N, Isonishi S, Hinotsu S, Hirose M, Katsura J.
Gan To Kagaku Ryoho. 2008 Feb;35(2):351-60. Japanese.
Molecularly targeted therapeutics for breast cancer.
Hussain SA, Palmer DH, Spooner D, Rea DW.
BioDrugs. 2007;21(4):215-24. Review.
Endocrine therapy and other targeted therapies for metastatic breast cancer.
Hussain SA, Palmer DH, Moon S, Rea DW.
Expert Rev Anticancer Ther. 2004 Dec;4(6):1179-95. Review.
The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents.
Drugs. 2000;60 Suppl 1:1-14; discussion 41-2. Review.
Molecular approach to breast cancer treatment.
Yarden Y, Baselga J, Miles D.
Semin Oncol. 2004 Oct;31(5 Suppl 10):6-13. Review.
Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd.
Drugs R D. 2003;4(4):243-8.
Novel fluoropyrimidines: improving the efficacy and tolerability of cytotoxic therapy.
Petty RD, Cassidy J.
Curr Cancer Drug Targets. 2004 Mar;4(2):191-204. Review.
Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations.
Broxterman HJ, Georgopapadakou NH.
Drug Resist Updat. 2005 Aug;8(4):183-97. Epub 2005 Sep 9.
The curability of breast cancer and the treatment of advanced disease.
Guarneri V, Conte PF.
Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S149-61. Epub 2004 Apr 24. Review.
Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV.
Acc Chem Res. 2008 Jan;41(1):98-107. Epub 2007 Aug 18. Review.
Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
[No authors listed]
Drugs R D. 2007;8(5):321-34. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on